News and Announcements
CBL Markets Acquires Australia’s H2OX
- Published June 22, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- CBL Markets and H2OX are set to merge.
- CBL has made good progress in their acquisitions of two US environmental businesses.
- PW Partners is raising funds for the two US acquisitions.
In September 2017, CBL Markets signed an agreement to acquire a controlling interest in the Australian Water Exchange, H2OX Markets Limited. CBL is also planning on acquiring two United States companies which are making good progress. The acquisition of H2OX allows CBL Markets to expand its product set beyond energy and environmental settings and in soft commodities.
Perella Weinberg Partners puts financial support and security over the CBL Acquisitions. PW Partners generate billions of dollars in funds, by having their engagement into CBL’s acquisition re-risks the funding and suggests a successful IPO of the merged group. H2OX supports the efforts made by CBL Markets in acquiring and consolidating of environmental businesses.
CBL markets set a record in April 2018, having a 32.7% increase in transactions over March 2018. CBL’s consolidated gross revenue exceeds USD 37m in 2018 and is projected to be nearly USD 46m in 2019. H2OX is confident in their decision to deliver strong financial outcomes despite the figures being behind initial expectations. H2OX will offer their investors an exit opportunity.
About H2OX
H2OX is a unique opportunity to invest in an exchange technology business that is disrupting the $2.6 billion p.a. Murray Darling Basin (MDB) water market. The financial, transaction expediency, and transparency benefits to MDB irrigators is compelling.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
